{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/prescribing-information/baclofen/","result":{"pageContext":{"chapter":{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen","depth":2,"htmlHeader":"<!-- begin field 0bca4e3c-f0b6-4588-82f9-a79f00ae765a --><h2>Baclofen</h2><!-- end field 0bca4e3c-f0b6-4588-82f9-a79f00ae765a -->","summary":"","htmlStringContent":"<!-- begin item 3956dc32-c2d2-4490-8052-a79f00ae7500 --><!-- end item 3956dc32-c2d2-4490-8052-a79f00ae7500 -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"edace7ac-83b8-5cf1-87da-709d39382122","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f09ad441-9e7f-5f11-9dc7-8cc051923ec2","slug":"doses","fullItemName":"Doses","depth":3,"htmlHeader":"<!-- begin field b8de84d9-063e-4771-a868-a79f00c2dc33 --><h3>What doses of baclofen are indicated for spasticity?</h3><!-- end field b8de84d9-063e-4771-a868-a79f00c2dc33 -->","summary":"","htmlStringContent":"<!-- begin item aff57ee4-a052-4af4-b8f8-a79f00c2da94 --><!-- begin field 60dd9d7e-8d98-4f03-9768-a79f00c2dc33 --><ul><li><strong>The dose of baclofen often needs adjustment to suit each person — for chronic severe spasticity resulting from multiple sclerosis:</strong><ul><li>Initiate at 5 mg three times a day.</li><li>Dosage can be gradually titrated up depending on response — a maintenance dose of 60 mg per day in three divided doses usually leads to satisfactory control of symptoms but careful adjustment depending on individual needs is required.</li><li>Maximum dose is 100 mg daily in divided doses.</li></ul></li><li><strong>Experimenting with dose regimens may be useful. For example:</strong><ul><li>Small frequent doses may be more beneficial in some people than larger spaced doses.</li><li>Some people benefit from a dose just at bedtime to counteract painful flexor night-time spasms.</li><li>A single dose taken about an hour prior to doing specific tasks such as washing, shaving, dressing, or physiotherapy may be beneficial.</li></ul></li><li><strong>If there is no benefit within 6 weeks of achieving maximum dose then consider stopping treatment.</strong></li><li><strong>When stopping baclofen avoid abrupt withdrawal (unless serious adverse effects occur): </strong><ul><li>Discontinue by gradual dose reduction over at least 1–2 weeks (longer if withdrawal symptoms occur).</li><li>Symptoms that may occur on abrupt withdrawal include: anxiety, confusional states, psychosis, hyperthermia, convulsions, tachycardia, and temporary aggravation of spasticity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BNF, 2020</a>]</p><!-- end field 60dd9d7e-8d98-4f03-9768-a79f00c2dc33 --><!-- end item aff57ee4-a052-4af4-b8f8-a79f00c2da94 -->","subChapters":[]},{"id":"76c64849-fc5b-50be-9641-27f44c73ec93","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 363113a1-4303-4ed4-b956-a79f00c2ee09 --><h3>What are the contraindications for baclofen?</h3><!-- end field 363113a1-4303-4ed4-b956-a79f00c2ee09 -->","summary":"","htmlStringContent":"<!-- begin item d421fc58-9bbd-423c-a7e9-a79f00c2ece0 --><!-- begin field 42d46111-edc1-478f-a1dd-a79f00c2ee09 --><ul><li class=\"MsoNormal\" style=\"line-height: normal;\"><strong>Do not prescribe baclofen to people with:</strong> <ul><li>Rare hereditary conditions of porphyria, galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li><li>Active peptic ulceration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BNF, 2020</a>]</p><!-- end field 42d46111-edc1-478f-a1dd-a79f00c2ee09 --><!-- end item d421fc58-9bbd-423c-a7e9-a79f00c2ece0 -->","subChapters":[]},{"id":"ffee4493-6504-5e8f-b654-1b3ec940ea31","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field 5c700804-2899-426a-8b43-a79f00c30137 --><h3>What are the cautions when using baclofen?</h3><!-- end field 5c700804-2899-426a-8b43-a79f00c30137 -->","summary":"","htmlStringContent":"<!-- begin item 20f6e776-834f-4a8e-9b71-a79f00c30039 --><!-- begin field edc3e601-15a9-4eac-9038-a79f00c30137 --><ul><li class=\"MsoNormal\" style=\"line-height: normal;\"><strong>Prescribe baclofen with caution to people:</strong><ul><li>With cerebrovascular disease.</li><li>With Parkinson's disease.</li><li>With diabetes mellitus.</li><li>Who are elderly.</li><li>With respiratory, hepatic, or renal impairment — in patients with impaired renal function or undergoing chronic haemodialysis, very low dosage should be used (for example 5 mg once daily). Only use in end-stage renal failure if expected benefits outweigh risks and monitor carefully for toxicity.</li><li>With a history of peptic ulceration.</li><li>With bladder sphincter hypertonia.</li><li>With epilepsy.</li><li>With severe psychiatric disorders — may be exacerbated by baclofen, especially increased risk of attempted suicide.</li><li>With people who are at risk of misuse, abuse, and dependence. </li><li>Taking certain <a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/prescribing-information/baclofen/#drug-interactions\">other drugs</a>.<span class=\"MsoHyperlink\"></span></li></ul></li><li><strong>Pregnancy:</strong> <ul><li>The manufacturer advises use only if potential benefit outweighs risk as studies in animals have shown reproductive toxicity.</li></ul></li><li><strong>Driving and using machinery:</strong> <ul><li>Baclofen may cause drowsiness and may affect performance of skilled tasks (such as driving). The effects of alcohol are enhanced.</li></ul></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/prescribing-information/baclofen/#doses\">Avoid abrupt withdrawal</a> — discontinue by gradual dose reduction over at least 1–2 weeks.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BNF, 2020</a>]</p><!-- end field edc3e601-15a9-4eac-9038-a79f00c30137 --><!-- end item 20f6e776-834f-4a8e-9b71-a79f00c30039 -->","subChapters":[]},{"id":"5ecda203-0d8f-5ab7-a671-1d1bbd1584d8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 48a85f35-1e01-4e24-b0cb-a79f00c31819 --><h3>What are the adverse effects of baclofen?</h3><!-- end field 48a85f35-1e01-4e24-b0cb-a79f00c31819 -->","summary":"","htmlStringContent":"<!-- begin item 95ab2d32-54e5-42db-beae-a79f00c316e9 --><!-- begin field 0cc6ac8d-ec44-4f90-8e0c-a79f00c31819 --><p><strong>The most commonly reported adverse effects of baclofen are drowsiness and nausea.</strong></p><ul><li>These occur mainly at the start of treatment, often if the dose is increased too rapidly. They may be transitory and eased by reducing the dose.</li></ul><p><strong>Other common side-effects include:</strong></p><ul><li>Fatigue, confusion, dizziness, hallucination, depression, ataxia, headache, dry mouth, gastrointestinal disorders, muscle weakness, myalgia, respiratory depression and sleep disorders, visual impairment, hypotension, rash, hyperhidrosis, enuresia, and dysuria.</li></ul><p><strong>Rare or very rare adverse effects with oral use include:</strong></p><ul><li>Abdominal pain, erectile dysfunction, hepatic dysfunction, altered taste.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BNF, 2020</a>]</p><!-- end field 0cc6ac8d-ec44-4f90-8e0c-a79f00c31819 --><!-- end item 95ab2d32-54e5-42db-beae-a79f00c316e9 -->","subChapters":[]},{"id":"ab88f9b4-27f6-5eaf-ad12-96174b4f7558","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0296ac98-5c6e-4329-b246-a79f00c330e9 --><h3>What drug interactions are associated with baclofen?</h3><!-- end field 0296ac98-5c6e-4329-b246-a79f00c330e9 -->","summary":"","htmlStringContent":"<!-- begin item 78bb3021-265e-46cc-a677-a79f00c32fa0 --><!-- begin field 259a9bab-f570-4aa9-9e2f-a79f00c330e9 --><ul><li class=\"MsoNormal\" style=\"line-height: normal;\"><strong>Baclofen has the potential to interact with:</strong> <ul><li>Alcohol, other muscle relaxants (such as tizanidine), opiates, anxiolytics, and hypnotics — may exacerbate the drowsiness and respiratory depressive effects of baclofen.</li><li>Tricyclic antidepressants — can enhance the muscle relaxant effects of baclofen, resulting in profound muscle hypotonia. Tricyclic antidepressants can also cause drowsiness that may be additive when taking baclofen.</li><li>Antihypertensives and diuretics — may potentiate the hypotensive effect of baclofen. It may be necessary to adjust doses of antihypertensive drugs.</li><li>Dopaminergics — there are reports of hallucination, confusion, headache, and nausea in people with parkinsonism shortly after baclofen was added to their medication.</li><li>Lithium — people taking both lithium and baclofen should be monitored for severe aggravation of hyperkinetic symptoms, especially in people with Huntington's chorea.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — may decrease excretion of baclofen.</li></ul></li></ul><p class=\"MsoNormal\">[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BNF, 2020</a>]</p><!-- end field 259a9bab-f570-4aa9-9e2f-a79f00c330e9 --><!-- end item 78bb3021-265e-46cc-a677-a79f00c32fa0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}